Selegiline hydrochloride

Details:

Selegiline is a smart-drug that works as a permanent MAO-B inhibitor. It also breaks down in the body to L-methamphetamine and L-amphetamine. It is typically prescribed to Parkinsons disease patients. It both promotes the release of dopamine and inhibits the update and destruction of dopamine. So, it works at both ends of the dopamine spectrum, and overall increases the amount of dopamine in the brain.

Joseph Knoll discovered Selegiline in the 1960s in Hungary. Knoll was interested specifically in what separated high-performing individuals from low-performing individuals. He decided that he wanted to design a drug that had both the dopamine releasing power of the amphetamine family, while at the same time had the unique magic of Monoamine-Oxidase Inhibitors.

As a Nootropic, Selegiline has been used fairly extensively. Although it is currently approved for the treatment of Parkinsons disease, one need only look at the original idea of the molecule to understand its nature. That is to say, it was developed specifically as a nootropic. It was developed as a way to study high-performing individuals, and seeing if it was possible to replicate those through pharmaceuticals.

Selegiline is typically available as either a pill to be taken orally or as a transdermal patch. Although dosages are similar (typically 5-10mg), the transdermal patch has a much higher bioavailability, which allows the body to process it. Blood serum levels of a 6mg transdermal patch matched the same serum levels as a 200mg oral dosage of Selegiline. Please be careful and keep this in mind when selecting a route of administration for Selegiline.